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Objective: The objective of this study was to quantify
time spent plus out-of-pocket costs associated with con-
ﬁrmed respiratory syncytial virus (RSV) hospitalization of
infants not prophylaxed against RSV.
Methods: A prospective survey was carried out at multi-
ple tertiary care hospitals in the United States.
Patients: The patients consisted of a consecutive sample
of infants <12 months, born between 33 and 35 weeks of
gestation. One site also enrolled full-term infants hospi-
talized with conﬁrmed RSV. Daily patient census identi-
ﬁed eligible patients. Consenting caregivers of eligible
subjects (n = 84, 1 refusal) were interviewed on discharge
day and by telephone ~30 days following discharge
regarding time and out-of-pocket costs due to RSV.
Results: Total average out of pocket expenses were
$643.69 (range $21–$16,867; SD $2,403) for premature
and $214.42 (range $6–$827; SD $218) (P = .0158) for
full-term subjects. Total average economic burden per
admission was $4517.07 for premature and $2135.30 for
full-term infants, including the value of lost productivity
but excluding inpatient hospital and physician bills and
lost income. Premature infants (n = 48) had longer 
hospital stays (mean 6.9 days; SD 7.5 vs. 3.4 days; 
SD 2.6 days) (P = .001) with an associated mean total
time spent by up to 5 adults of 281.7 hours (range
25–2819.7 hours; SD 465.8 hours) versus a mean of
139.7 hours (range 31.8–561.3 hours; SD 118.1 hours)
for term infants (P = .109). Time and out-of-pocket costs
continued after discharge.
Conclusions: RSV hospitalization of infants is associated
with substantial, previously unmeasured time and mone-
tary losses. These losses continued following discharge.
The economic burden on families and society appears
heavier for infants born at 33 to 35 weeks of gestation
than for full-term infants.
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ABSTRACT
Introduction
Respiratory syncytial virus (RSV) is the leading
cause of hospitalization of infants under the age of
1 year in the United States [1]. Published studies 
of the economic burden associated with RSV hos-
pitalization and the potential cost-effectiveness 
of passive prophylaxis with either RSV-IGIV or
palivizumab (MedImmune, Inc., Gaithersburg,
MD) have focused on hospital charges and, except
for one US study of presumed RSV cases [2], have
not directly asked families of hospitalized infants
about their time and out-of-pocket costs due to RSV
[3–6].
Cost-effectiveness analyses should be performed
from a societal (compared to a payer’s) perspective
and should include all direct and indirect costs,
including pain and suffering, lost productivity, and
outpatient costs [7]. It is therefore important to
measure directly the time and monetary impact 
of RSV hospitalization on families of acutely ill
infants.
Objective
The purpose of this study was to measure a com-
ponent of the economic burden of RSV hospital-
ization by asking parents or primary caregivers of
hospitalized infants about time and out-of-pocket
costs associated with the RSV hospitalization and
estimating the societal value of lost productivity 
by affected adults. Speciﬁcally, the study sought to
ascertain the burden on families of premature
infants born between 33 and 35 weeks of gestation
hospitalized for RSV. This gestational age group
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was selected because cost considerations are
invoked as a reason for reserving RSV prophylaxis
to infants with additional risk factors [8]. Compa-
rable data were collected for an unmatched cohort
of full-term infants hospitalized with RSV.
Methods
A prospective survey was conducted in 10 geo-
graphically diverse tertiary care hospitals with pedi-
atric intensive care units in the United States (see
Acknowledgments). The study was intended to be
descriptive and was not powered to be representa-
tive of the universe of potential subjects. The survey
methods have been described previously [9].
The study was initiated in February 2000 and
continued through April 2001. After receiving
approval from each center’s institutional review
board (IRB) and one IRB at an afﬁliated university,
a daily patient census was taken to identify all inpa-
tient infants under the age of 1 year, born between
33 and 35 weeks of gestation, with a laboratory
conﬁrmed, RSV infection who had not received 
prophylaxis against RSV with either RSV-IGIV or
palivizumab and who were not enrolled in any clin-
ical trial. Full-term infants were enrolled at one of
the 10 sites using identical methods. All such infants
were eligible for inclusion in the study. Parent/
caregivers (hereafter, informants) were excluded if
they were unable to understand or communicate in
either English or Spanish. After receiving informed
consent, demographic, diagnostic, and insurance
data were abstracted from the medical and hospital
records of enrolled infants. Also abstracted were the
infant’s admission and discharge dates and whether
admission to the intensive care unit occurred during
the hospital stay. A trained physician or nurse, using
a printed survey instrument, interviewed informants
on the day of discharge. Informants were asked
about their own experiences and that of up to four
other hospital visitors. All responses were recorded
verbatim. Approximately 30 days later, the infor-
mant was reinterviewed by telephone. Informants
received a $25 honorarium for each phase of the
interview for a possible total of $50.
Completed surveys were manually reviewed for
clarity and logic, double veriﬁed during data entry,
and analyzed using SAS, version 6.12 (SAS Institute,
Cary, NC).
Continuous variables were tested for signiﬁcant
differences using the Wilcoxon rank sum test. Cat-
egorical variables were tested using Fisher’s exact
test or Pearson’s chi-square, depending on the
number of categories. A P value of .05 was consid-
ered statistically signiﬁcant. Total out-of-pocket
costs were subjected to regression analysis.
Results
A total of 48 premature and 36 full-term infants
were enrolled in this study. Only one parent of 
an eligible full-term infant refused to participate in 
the survey. Follow-up interviews approximately
30 days after discharge were completed for all but
3 premature and 3 full-term infants. One of the pre-
mature infants died of SIDS the day after hospital
discharge; one parent of a full-term infant lost
custody of her children and efforts to contact 
the remaining parents were unsuccessful despite
repeated efforts by telephone and in writing. Three
informants were foster mothers; one was an aunt,
and the remainder were parents.
Table 1 shows the demographic and insurance
characteristics of the study infants. Not shown is
the fact that among the premature cohort there
were three sets of twins, two of which were simul-
taneously hospitalized and one set that overlapped
while one twin had a longer stay. Each infant’s hos-
pital stay was treated as a separate event. One pre-
mature and one full-term infant were readmitted to
the same hospital for RSV infection and studied
twice during the same RSV season. Enrolled pre-
mature infants were signiﬁcantly more likely to be
African American than white (P = .001) and to 
have lower weight at hospital admission for RSV
(P = .0009).
Table 2 describes the inpatient stay. Premature
infants had a signiﬁcantly longer hospital stay
(P = .003) but were not more likely to be admitted
to the ICU. In fact, ICU admission, which occurred
in a high percentage of both groups of infants, was
not signiﬁcantly associated with degree of prema-
turity, race, or type of insurance. Length of stay
(LOS) did not vary signiﬁcantly by degree of pre-
maturity, race, or type of insurance.
Inpatient Stay
In this study, numerous adults including parents,
grandparents, extended family, and friends visited
hospitalized infants. Premature infants were
reported to have been visited by more adults with
a mean of 4.5 (median 4; range 2–17; SD 2.6) adult
visitors compared with a mean of 3.5 (median 3;
range 2–11; SD 1.8) for full-term infants (P = .03).
Total average time spent traveling to and from the
hospital as well as time spent in the hospital is
shown in Table 3. The time burden associated with
hospital visits to premature infants was more than
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Table 1 Patient characteristics
33–35 weeks of gestation (N = 48) Full-term (N = 36)
Sex*
Male 28 (58) 16 (44)
Race/ethnicity*†
Caucasian 23 (47) 32 (89)
Black 15 (31) 3 (8)
Hispanic 11 (22) 1 (3)
Native American/Paciﬁc Islander 0 (0) 0 (0)
Asian 1 (3) 1 (3)
Age at admission (months)
Mean (range) 4 (0.5–11.9) 4.2 (0.2–11.0)
Median 2.4 3.0
Admission weight (g) 4812.4 6480.9
Mean (range) (801–10500) (2400–10745)
Median 4250 6488.5
SD 2220.3 2239.9
Primary insurance*
Commercial, BC/BS 21 (43) 21 (59)
Medicaid 23 (48) 13 (36)
CHAMPUS/VA 1 (2) 0 (0)
Indian Health Service 2 (4) 1 (3)
Uninsured 1 (2) 1 (3)
*Number (%).
†Patients who chose more than one race/ethnicity were counted multiple times.
Table 2 Inpatient experience
33–35 weeks of gestation (N = 48) Full-term (N = 36)
Length of stay (days)
Mean (range) 7.0 (0–45) 3.4 (1–10)
Median 4 2.0
SD 7.5 2.6
Primary discharge diagnosis*
RSV bronchiolitis 45 (94) 28 (78)
RSV pneumonia 2 (4) 2 (6)
Other RSV 0 (0) 6 (17)
Hyponatremia 1 (2) 0 (0)
ICU admission 20 (42) 12 (33)
*Number (%).
Table 3 Time burden associated with hospital visits
33–35 weeks of gestation (N = 48) Full-term (N = 36)
Primary caregiver
Total travel time (hours)
Mean (range) 6.8 (0.13–48) 2.2 (0.17–9)
Median 4.5 2.0
SD 8.5 1.9
Time together in hospital (hours)
Mean 133.6 (14–1080) 80.5 (10–240)
Median 84 58
SD 176.0 65.1
Other visitors (up to 4)
Time traveling and in hospital (hours)
Mean (range) 139.1 (0–1728) 52.8 (0–342)
Median 47.5 27.5
SD 293.4 73.0
Total average time (range) 281.7 (25–2819.7) 139.7 (31.8–561.3)
Median 142.4 94.2
SD 465.8 118.1
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twice the total average time associated with full-
term infants.
Informants were asked about their own out-of-
pocket payments for travel, parking, meals in the
hospital, added costs for child care, and other
expenses incurred due to the RSV hospitalization as
well as those incurred by up to four other visitors,
if known (Table 4).
Responses to the question (exclude medical and
hospital bills) “Did you or other caregivers have any
additional expenses you didn’t mention yet because
the baby was in the hospital?” were afﬁrmative for
21 of the full-term infants and 16 of the premature
infants. Those who answered “yes” to the question
were asked to specify the type of expense and were
asked, “Altogether, about how much did that cost?”
Not shown are categories of reported expenses such
as purchase of a nebulizer (5 infants), a humidiﬁer
(6 infants), and speciﬁc amounts of lost wages
during the hospital stay.
Informants were also asked for the number of
siblings to direct questions about altered child-care
arrangements for siblings at home. The premature
infants had signiﬁcantly more siblings (mean 2;
median 2; range 0–6; SD 1.8) than full-term infants
(mean 1.2; median 1; range 0–4; SD 0.9) (P = .08).
Informants for premature infants with siblings
(n = 18) reported higher direct costs for altered child
care during the hospital stay than for full-term
infants (n = 10) (mean $148.39 vs. $59.50; median
$100 vs. $22.50; SD 155.9 vs. 80.8) (P = .017).
After Discharge
Full-term infants in this study were reported to have
more follow-up physician visits (mean 2.5; median
2; range 1–5; SD 1.4) than premature infants (mean
1.8; median 1; range 1–5; SD 1.1). Associated time
for these visits averaged 4.7 hours (median
2.5 hours; range 0.1–20 hours; SD 4.9 hours) for
full-term infants compared to a mean of 3.1 hours
(median 2.5 hours; range 0.5–10 hours; SD
2.5 hours) for the premature infants. Out-of-pocket
costs following discharge averaged $48.40 (median
$13; range $0–$341; SD $77.3) for premature
infants compared with $71.64 (median $34; range
$0–$650; SD $114.0) for full-term infants
(P = .1757).
Responses to all questions about out-of-pocket
costs were summed to ascertain total average out-
of-pocket payments per infant during and follow-
ing the RSV hospitalization. Average payments per
premature infant were $644 (median $216; range
$21–$16,867; SD 2403.2); three times the amount
reported for full-term infants (mean $214; median
$131; range $6–$827; SD $218.3) (P = .0158).
Excluding the one premature infant with extremely
high out-of-pocket costs resulted in a mean of $299
(median $202; range $21–$1203; SD $240.3). Total
average time spent was 281.67 (median 142.4;
range 25–2819.7; SD 464.8) hours per premature
infant compared with 139.72 hours per full-term
infant (median 94.2 hours; range 31.8–561.3 hours;
SD 118.1 hours) (P = .1086). To estimate the value
to society of lost productivity during the RSV hos-
pitalization and the subsequent month, reported
total average time spent by up to ﬁve adults per
infant was multiplied by the average hourly wage
of employees in 2000 ($13.75) [10]. When reported
out-of-pocket payments by up to ﬁve adults per
infant were added to the estimated value of lost pro-
ductivity due to RSV, the total economic burden to
families and society was calculated to have been
$4457.07 per premature infant and $2135.30 per
full-term infant (Fig. 1). These dollar amounts do
Table 4 Out-of-pocket costs associated with hospital visits
33–35 weeks of gestation (N = 49) Full-term (N = 36)
Travel and parking ($)
Mean (range) 43.7 (1–404) 13.5 (0–116.3)
Median 25 9.0
SD 63.1 20.6
Cost of meals ($)
Mean (range) 75.8 (5–500) 49 (1–300)
Median 32.5 30
SD 92.3 64
Child care ($)
Mean (range) 148.4 (30–600) 59.5 (0–205)
Median 100 22.5
SD 155.9 80.8
Other expenses ($)
Mean (range) 1018.2 (5–15,000) 79.1 (3–486)
Median 62.5 20
SD 3852.9 128
104 Leader et al.
not include lost income reported by those self-
employed and those without sick leave beneﬁts. It
also does not include the value of lost productivity
of volunteers who looked after siblings during the
hospital stay. Also not included is the families’
ﬁnancial liability for the hospital stay.
We compared the reported direct out-of-pocket
expenses for all infants who were either enrolled in
Medicaid or the Indian Health Service or who were
uninsured (n = 39) with infants covered by either
commercial insurance or Blue Cross/Blue Shield
(n = 42). One subject, insured by CHAMPUS, 
and two with insurance described as “other” were
excluded from this analysis. Total average out-
of-pocket payments were $652.36 for the latter
families (median $169; range $21–$16,867; SD
$2571.8) compared with $267.39 for families with
either public or no insurance (median $189; range
$6–$1203; SD $261.1) (P = .514). Mean out-of-
pocket expenses for premature infants with public
or no insurance (n = 25) was $333.84 (median
$285; range $42–$1203; SD 281.2) compared with
$1052.19 (median $180; range $21–$16,867; SD
$3628.3) for premature infants with private insur-
ance (n = 21) (P = .724).
We also examined the impact of ICU admission
on total out-of-pocket cost within the cohort of 
premature infants. Total mean cost for infants in 
the ICU was $1,192.05 (median $372.5; range
$47–$16,867; SD $3,699.6) versus $252 (median
$171.5; range $21–$770; SD $200.8) for those
infants who were not in the ICU (P = .058).
LOS, infant age, weight, prematurity status, 
sex, race, and insurance source were entered into a
regression model of total out-of-pocket cost. Only
LOS was signiﬁcant (P = .02).
Discussion
This survey about the time and out-of-pocket costs
incurred during and following an infant’s hospital-
ization for a laboratory-conﬁrmed RSV infection is
the ﬁrst such effort in the United States. The survey
revealed that each such hospitalization resulted in
time, out-of-pocket, and productivity losses by
numerous concerned adults. Furthermore, these
costs continued for at least 1 month after discharge.
These costs have not been fully accounted for in
published studies of the cost-effectiveness of passive
prophylaxis against RSV hospitalization.
Kaplan-Machlis and Beane [2] conducted a tele-
phone interview of parents of both premature and
full-term infants with chronic lung disease about
their time and monetary costs, but the presumed
RSV cases had not been virologically conﬁrmed. A
cost-effectiveness model of RSV-IGIV included an
estimate of the value of time for one parent to bring
an infant for prophylaxis but did not include
parental time or out-of-pocket costs associated with
a RSV hospitalization [3]. Another cost-effective-
ness model included an estimate of the value of one
parent’s time in either seeking outpatient prophy-
laxis or remaining continuously with their infant in
the hospital during a RSV stay but no other time or
monetary costs were included [5].
One survey of parents of 79 children hospitalized
with RSV in the Netherlands asked about lost
workdays, cost of travel and extra child care, pre-
scribed drugs, and physician consultations 2 weeks
before and after the hospital stay. However, the
infants studied were predominantly full-term. The
infants were reported to have been ill for 4 days and
to have had a median of two doctor visits before
hospital admission. The authors concluded that
15% of the total cost of the RSV hospitalization
was borne by parents and that the costs would
likely be higher for a high-risk population and for
infants admitted to the intensive care unit [11]. Our
data show that costs were higher for premature
infants hospitalized with RSV. While we did calcu-
late tests of signiﬁcance for observed variance
between the premature and full-term infants, the
cohorts were not truly comparable because the full-
term infants were only enrolled at one participating
hospital.
Although we believe that our survey data are the
most comprehensive evaluation to date of time and
out-of-pocket costs due to RSV hospitalization in
the United States, there are several reasons why the
results may underestimate actual costs. First, time
and out-of-pocket costs incurred before the hospi-
talization were not captured. Costs more than 1
month after discharge were also captured in this
study.
A retrospective chart review of conﬁrmed RSV
cases admitted to one US hospital between 1995
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Figure 1 Estimated lost productivity and total economic burden 
per hospitalized infant. Total time (281.7 hours premature and
139.7 hours for full-terms infants) ¥ $13.75 per hour [10].
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and 1998 found that 61% of the cases had been
treated by a physician for respiratory related illness
during the week before admission, 46% had a prior
respiratory-related emergency room visit, 38% had
a related emergency room visit after discharge, and
43% were referred to a respiratory specialist for
follow-up care [12]. These data suggest that the 
economic burden of RSV is greater than the costs
associated with the inpatient stay alone and the
follow-up period evaluated here.
In this survey, total direct medical costs to fami-
lies were also not captured because that infor-
mation was not likely to be known during the
interviews (medical bills often take months to be
ﬁnally adjudicated with insurance companies).
Because of this anticipated delay, the survey did not
ask for the direct cost of insurance deductibles,
copayments for the inpatient stay, or uncovered
portions of medical bills. Therefore, the total
reported out-of-pocket amounts might understate
the family’s ﬁnancial burden. Many informants
reported speciﬁc amounts of lost income and other
ﬁnancial losses. However, that information was not
speciﬁcally requested of all informants, and thus
true ﬁnancial burden may be further understated.
Because informants were asked, “While the baby
was here in the hospital, including the day you
brought him or her, did you have to pay a baby
sitter or day care center for any new or additional
help in watching these other children because the
baby was sick?” we did not systematically capture
information about the amount of time volunteers
donated as babysitters. A number of informants
reported extensive time and monetary losses by
these volunteers, but these amounts are not
included in the totals reported above. Additionally,
no information about ongoing RSV-related costs
beyond the 30th day after discharge were captured.
Of interest, informants reported that 22% of the
premature infants and 25% of the full-term infants
had more than one “RSV” admission. While these
reports were not conﬁrmed from the medical record
during the study, if correct, this could add signiﬁ-
cantly to the time and out-of-pocket costs. Unfor-
tunately, the costs of multiple RSV admissions
during a single season were not speciﬁcally cap-
tured. Future studies should examine costs incurred
before hospitalization as well as those associated
with multiple RSV admissions.
As with any survey, there may have been recall
bias and most of the time and monetary costs were
not independently veriﬁed except for logical consis-
tency (e.g., the visit time in the hospital could not
exceed the infant’s length of stay). We did not verify
reported costs for other visitors and do not know
how reliable this information is. However, there 
is no reason to assume that results for full-term
infants would be systematically remembered differ-
ently than those for premature infants. Because
informants were interviewed on the day of dis-
charge, their memories should have been fresh.
Informants were also told in advance when they
would be telephoned about their postdischarge
experiences, so they may have been making a con-
scious effort to remember their RSV-related experi-
ences during that period.
Finally, while the speciﬁc dollar amounts
reported here may not be conﬁdently generalized to
the universe of such admissions, the inpatient expe-
riences of our subjects do not seem atypical. For
example, the observed ICU admission rates are 
consistent with a recent report from 10 children’s
medical centers [13].
Conclusion
The results of this survey indicate that RSV hospi-
talization is associated with substantial time and
direct monetary losses to affected families and 
signiﬁcant losses in productivity from a societal 
perspective. We found that RSV hospitalization of
premature infants born between 33 and 35 weeks
of gestation imposes substantial economic burdens
on families and society. The comparable burdens
were less for full-term infants at one of the study
sites. Because the results of this survey did not
include prehospitalization costs, all medical
expenses, or costs of multiple RSV hospitalizations,
the total economic burden of RSV hospitalization
of infants remains to be documented. But, evidence
from this survey demonstrates that the economic
burden from RSV hospitalization is much greater
than hospital charges alone.
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